Quote:As the current price is 1.80, are you suggesting it will rise over $4 in the coming months and not require a reverse split?
I’ll hope that, but also suggest it as well. There’s no sure thing, but just consider:
Revenue
Veneto 12 months ending June 30 2018
$73,673,000
https://www.sec.gov/Archives/edgar/data/10597...ex99_3.htm
Fuse 9 months ending September 30 2018
$18,506,810
http://fzmd.ir.edgar-online.com/fetchFilingFr...Q_20181113
Fuse 10k is pending. They’re hoping to see 12 month revenue near $30 million, but we have to wait to see, and I may recall that incorrectly. $25 million certainly appears realistic.
Hospital Chain
I believe we heard $100 million in yearly revenue. I need to relisten to the CC since I was distracted at work. If so, and assuming a deal closes, these three companies alone equate to approximately $200 million yearly in revenue. That’s almost double the current market cap.
Pantheon and Medisource
Private companies but their combined handful of million in revenue brings us to the total in revenue that is double the current market cap.
Olaregen
Commercialization begins. As does pending news about data presented at two upcoming scientific events. That’s pretty significant for an otcbb biotech, especially since Generex infused money into Excellagen for clinical development and the commercialization effort which was not happening under previous ownership of Excellagen.
Regentys
I’ll leave that be for now, although Generex also just expended money for clinical development. Yet it’s another area for positive news.
NGIO
A clinical trial with Merck’s Keytruda is set to commence. Trial sites are set including the Cleveland Clinic. Enrollment to commence. First patient dosed amongst other updates to come.
A merger agreement is to be announced.
A collaboration for neoantigens is to be announced.
An agreement to acquire IP from a top research institute is to be announced.
A spin out with a listing on a major exchange is to be announced.
NuGenerex Distribution
Veneto, Fuse, Medisource, Pantheon to benefit as the model including their own pharmacies and MSO network is to expand into more states- 27 total but incremental advancement may be announced.
A direct to patient pharmacy business is set to be acquired that I think is nationwide.
A medical food type business is set to be acquired.
NuGenerex Diagnostics
Updates may ensue short term but I missed that update on the CC. However, this subsidiary shouldn’t be overlooked.
National Bank
We need more info to learn of this future funding source.
Current Financings
Gnbt is still for now on the otcbb so the funding is what it is, but if you read the exhibits attached to the 8k’s you see no money can go to executive salaries. It all goes to business development ie. Olaregen commercialization and Regentys’ clinical needs.
Generex needs $5 million cash for the hospital chain, but that sounds extremely worthwhile.
Dividend Pool
Joe and three principals gifted to Generex around 35 million shares, I’m guessing that total, which is being used in acquisitions in a non dilutive fashion to the benefit of all shareholders. That is extremely unique. !!! Can you imagine the financing needs Generex would have without this generosity?
Management and BOD
$0 in cash salaries. I hope that changes soon since it would reflect Joe feeling comfortable in the companies financial footing and everyone deserves to get paid. But, cmon give him credit for his philosophy in this area and in not only pooling his shares but convincing Larry Salvo, Stephen Berkman and the other BH (something), plus gaining voting power on their abundance of pooled shares. He convinced them to believe. (Berkman, if spelt correctly, invested wel over $10 million into Hema aka NuGenerex Diagnostics, so he’s no fool.)
Execution is always paramount, but somehow that’s what’s unfolding. I say somehow because under Fletcher Gnbt was closing shop. Sec filings stopped. Joe and Salvo paid a significant amount of their personal cash to get filings up to speed, and at the time they had NO committed plan to be paid back. They eventually took shares. The dividends benefit us.
So yes, I’ll suggest an uplist without any reverse split, which would make no sense anyway for numerous reasons (liquidity, no need, not enough shares, etc etc etc).
6
